Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…
https://etira.life/wp-content/uploads/2024/06/image.jpeg12641756Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-06-20 10:43:312026-01-02 12:24:43DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
Dallas, TX – May 14th, 2024: Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This…
https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release.jpg5631000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-05-15 12:36:582026-01-02 12:23:51ERX-315 SUBMITTED FOR HREC APPROVAL
San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
https://etira.life/wp-content/uploads/2024/05/Unknown-scaled.jpeg19202560Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-04-10 11:35:082026-01-02 12:21:28ERX-208 potency in Ovarian Cancer
Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
https://etira.life/wp-content/uploads/2024/01/image.png8661098Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-01-24 11:44:062026-01-02 12:19:56Targeting LIPA in ovarian cancer
San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple…
https://etira.life/wp-content/uploads/2024/02/image-1-scaled.jpeg19202560Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-12-07 11:10:162026-01-02 12:18:37ERX-315 introduced at SABCS 2023
Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…
https://etira.life/wp-content/uploads/2023/10/image.png5901000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-10-02 11:48:592026-01-02 12:17:04Independent validation of LIPA as a molecular target in TNBC
Dallas, Texas. June 1, 2023:
One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…
https://etira.life/wp-content/uploads/2023/06/nature-cancer-thumbnail.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-06-01 17:50:412023-11-30 12:45:37One year later, highest almetric score for any paper published in Nature Cancer!
Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…
https://etira.life/wp-content/uploads/2023/04/Annual-Meet-Feature-Image.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-04-18 16:49:332026-01-02 12:12:57Positive preclinical data presented at AACR 2023
Dallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
https://etira.life/wp-content/uploads/2023/04/UT-Health-Feature-Health.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2023-04-17 16:42:112024-02-13 11:16:08Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
Dallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…
https://etira.life/wp-content/uploads/2022/12/San-Antonio-Breast-Cancer-Thumbnail-1.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-12-09 15:45:172023-11-30 12:49:50Preclinical data on TNBC presented at SABCS 2022
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsERX-315 SUBMITTED FOR HREC APPROVAL
NewsERX-208 potency in Ovarian Cancer
NewsTargeting LIPA in ovarian cancer
NewsERX-315 introduced at SABCS 2023
NewsIndependent validation of LIPA as a molecular target in TNBC
NewsOne year later, highest almetric score for any paper published in Nature Cancer!
NewsPositive preclinical data presented at AACR 2023
NewsEtira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsPreclinical data on TNBC presented at SABCS 2022
News